ARTICLE | Company News
bioMérieux grows China footprint with majority stake in Hybiome
November 16, 2018 5:38 PM UTC
Increasing its presence in China and the immunoassay market, France’s bioMérieux S.A. (Euronext:BIM) acquired a majority stake in fellow diagnostics company Suzhou Hybiome Biomedical Engineering Co. Ltd. (Suzhou, China).
bioMérieux said it acquired 54% of Hybiome shares for €89.1 million ($100.3 million), based on a valuation for Hybiome of €165 million ($185.8 million). In July, bioMérieux gained a minority stake in Hybiome...